RU2320343C2 - Способ лечения диабета - Google Patents

Способ лечения диабета Download PDF

Info

Publication number
RU2320343C2
RU2320343C2 RU2004133670/14A RU2004133670A RU2320343C2 RU 2320343 C2 RU2320343 C2 RU 2320343C2 RU 2004133670/14 A RU2004133670/14 A RU 2004133670/14A RU 2004133670 A RU2004133670 A RU 2004133670A RU 2320343 C2 RU2320343 C2 RU 2320343C2
Authority
RU
Russia
Prior art keywords
mammal
alkyl
compound
independently hydrogen
ranolazine
Prior art date
Application number
RU2004133670/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2004133670A (ru
Inventor
Эндрю ВОЛФФ (US)
Эндрю ВОЛФФ
Маркус ДЖЕРЛИНГ (US)
Маркус ДЖЕРЛИНГ
Original Assignee
Си Ви Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Си Ви Терапьютикс, Инк. filed Critical Си Ви Терапьютикс, Инк.
Publication of RU2004133670A publication Critical patent/RU2004133670A/ru
Application granted granted Critical
Publication of RU2320343C2 publication Critical patent/RU2320343C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2004133670/14A 2002-05-21 2003-05-21 Способ лечения диабета RU2320343C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38278102P 2002-05-21 2002-05-21
US60/382,781 2002-05-21
US45933203P 2003-03-31 2003-03-31
US60/459,332 2003-03-31

Publications (2)

Publication Number Publication Date
RU2004133670A RU2004133670A (ru) 2005-06-10
RU2320343C2 true RU2320343C2 (ru) 2008-03-27

Family

ID=29586970

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004133670/14A RU2320343C2 (ru) 2002-05-21 2003-05-21 Способ лечения диабета

Country Status (16)

Country Link
US (4) US20040063717A1 (enExample)
EP (2) EP1505977B1 (enExample)
JP (1) JP4546824B2 (enExample)
KR (1) KR101030943B1 (enExample)
CN (1) CN100551370C (enExample)
AU (1) AU2003248558B8 (enExample)
BR (1) BR0311161A (enExample)
CA (1) CA2486712C (enExample)
ES (1) ES2523873T3 (enExample)
IL (4) IL165304A0 (enExample)
MX (1) MXPA04011530A (enExample)
NO (1) NO330336B1 (enExample)
NZ (1) NZ536678A (enExample)
RU (1) RU2320343C2 (enExample)
WO (1) WO2003099281A2 (enExample)
ZA (1) ZA200409331B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2587624C2 (ru) * 2010-01-29 2016-06-20 Ридженерон Фармасьютикалз, Инк. Способы лечения диабета антагонистами dll4

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
MX2007008162A (es) * 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
JP2010523713A (ja) * 2007-04-12 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド インスリン分泌を増強するためのラノラジン
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
JP2010528112A (ja) * 2007-05-31 2010-08-19 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を治療する方法
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
US20110280941A1 (en) * 2008-12-11 2011-11-17 Mefford Scientific, Llc Compositions of proton pump inhibitors and insulin secretagogues, and methods of their use to treat diabetes
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN110812344A (zh) * 2019-12-17 2020-02-21 卓和药业集团有限公司 一种治疗糖尿病合并心绞痛的药物组合物及制备方法
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060348A2 (en) * 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
GB2202222B (en) * 1987-03-16 1991-03-27 American Home Prod Fluorooxirane carboxylates
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ES2177601T3 (es) 1989-06-23 2002-12-16 Syntex Llc Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
KR20010085373A (ko) * 1998-08-11 2001-09-07 노르우드 데이비드 씨. 포유류 말로닐 ＣｏＡ 데카복실라아제 억제제, 효능제 및길항제를 동정하기 위한 조성물 및 방법
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US20050245502A1 (en) 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
FR2805463B1 (fr) * 2000-02-25 2003-01-24 Adir UTILISATION DE LA TRIMETAZIDINE POUR L'OBTENTION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES A INHIBER L'ACYL-CoA ACETYLTRANSFERASE
US20030220312A1 (en) 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
AU2001263230B2 (en) 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
ATE357257T1 (de) 2000-07-27 2007-04-15 Pharmacia Corp Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
EP1385548B1 (en) 2001-01-26 2007-05-23 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
MXPA04000565A (es) * 2001-07-19 2005-06-17 Cv Therapeutics Inc Compuestos de piperazina sustituidos y su uso como inhibidores de oxidacion de acidos grasos.
US20030220310A1 (en) 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20050250676A1 (en) 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
US6958352B2 (en) 2002-02-08 2005-10-25 Smithkline Beecham Corporation Compounds for inhibiting insulin secretion and methods related thereto
US20080109040A1 (en) 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
AU2003248558B8 (en) 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2004079372A1 (en) 2003-03-05 2004-09-16 Metabolex Inc. Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-trp
AU2004248187A1 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
CA2568134A1 (en) 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
MX2007005367A (es) 2004-11-09 2007-06-18 Cv Therapeutics Inc Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.
MX2007008162A (es) 2005-01-06 2007-07-24 Cv Therapeutics Inc Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina.
US20060205727A1 (en) 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
US20080153840A1 (en) 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
CA2678272A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
EP2117549A1 (en) 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
JP2010518171A (ja) 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
US20090312340A1 (en) 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
JP2010528112A (ja) 2007-05-31 2010-08-19 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を治療する方法
CA2689633A1 (en) 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
BRPI0908428A2 (pt) 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
JP2012502047A (ja) 2008-09-04 2012-01-26 ギリアード サイエンシーズ， インコーポレイテッド 心房細動を治療する方法
WO2010068461A1 (en) 2008-11-25 2010-06-17 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
MX2011012140A (es) 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060348A2 (en) * 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
весь документ, особенно: с.2, лин.3-26, пп.1, 2, 4. *
Клиническая эндокринология. Рук. для врачей / Под ред. проф. Н.Т.Старковой. - М.: Медицина, 1991, с.199 абз.4, с.210, с.219-220, с.228 абз.4. COLLIER GR. et al. Effect of fatty acid oxidation inhibition on glucose metabolism in diabetic rats // Horm.Metab.Res. 1993 Jan; 25(1):9-12, реферат, онлайн [Найдено в Интернет 05.02.2007 на www.pubmed.com], PMID: 8428713. GRYNBERG A. Modifications du metabolisme energetique cardiaque chez le diabetique // Diabetes and Metabolism, Nov 2001, vol.27, no.5, Cahier 2, p.4S12-4S19. BARNETT М. et al. The longitudinal effect of inhibiting fatty acid oxidation in diabetic rats fed a high fat diet // Horm. Metab. Res. 1992 Aug; 24(8): 360-2, реферат, он-лайн [Найдено в Интернет 05.02.2007 на www.pubmed.com1, PMID: 1526621. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2587624C2 (ru) * 2010-01-29 2016-06-20 Ридженерон Фармасьютикалз, Инк. Способы лечения диабета антагонистами dll4

Also Published As

Publication number Publication date
WO2003099281A3 (en) 2004-04-01
US8883750B2 (en) 2014-11-11
WO2003099281A2 (en) 2003-12-04
IL165304A (en) 2011-08-31
US20130102555A1 (en) 2013-04-25
JP4546824B2 (ja) 2010-09-22
CN1652788A (zh) 2005-08-10
AU2003248558B8 (en) 2009-07-09
US20140378465A1 (en) 2014-12-25
NO330336B1 (no) 2011-03-28
IL165304A0 (en) 2006-01-15
ZA200409331B (en) 2005-06-29
US20040063717A1 (en) 2004-04-01
NO20045554L (no) 2004-12-20
JP2005532331A (ja) 2005-10-27
NZ536678A (en) 2007-01-26
EP1505977A2 (en) 2005-02-16
IL213809A0 (en) 2011-07-31
US20100197701A1 (en) 2010-08-05
ES2523873T3 (es) 2014-12-02
HK1073441A1 (en) 2005-10-07
AU2003248558B2 (en) 2009-03-12
AU2003248558A1 (en) 2003-12-12
KR20040111677A (ko) 2004-12-31
EP2332540A1 (en) 2011-06-15
MXPA04011530A (es) 2005-08-15
EP1505977B1 (en) 2014-09-10
CA2486712A1 (en) 2003-12-04
KR101030943B1 (ko) 2011-04-28
US8314104B2 (en) 2012-11-20
IL213806A0 (en) 2011-07-31
RU2004133670A (ru) 2005-06-10
BR0311161A (pt) 2005-03-29
CN100551370C (zh) 2009-10-21
CA2486712C (en) 2012-01-03

Similar Documents

Publication Publication Date Title
US8883750B2 (en) Method of treating diabetes
US6677342B2 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
CA2802335A1 (en) Controlled release compositions with reduced food effect
US8822473B2 (en) Method of treating diabetes
AU2007354300A1 (en) Method of treating diabetes
US20240307352A1 (en) Sacubitril valsartan sodium sustained-release composition, and preparation method therefor and use thereof
RU2442585C2 (ru) Способ лечения диабета
HK1073441B (en) Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes
US12527754B2 (en) Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions
CN101658673A (zh) 治疗糖尿病的方法
TR2023016131A1 (tr) Metformi̇n i̇çi̇n uzatilmiş salimli bi̇r formülasyon ve si̇tagli̇pti̇n i̇çeren hemen salimli formülasyon i̇çeren bi̇r tablet
HK1130181A (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PC41 Official registration of the transfer of exclusive right

Effective date: 20140702

MM4A The patent is invalid due to non-payment of fees

Effective date: 20150522